- Home
- DD vs DGX Comparison
DD vs DGX Comparison
Compare DD & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DD | DGX |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 22.6B |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DD | DGX |
|---|---|---|
| Price | $139.62 | $203.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $56.67 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 2.4M | 732.9K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | 1.79% | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 0.39 | ★ 2.24 |
| Revenue | ★ $20,397,000,000.00 | $11,035,000,000.00 |
| Revenue This Year | $6.72 | $7.53 |
| Revenue Next Year | $3.83 | $3.77 |
| P/E Ratio | $119.67 | ★ $88.03 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $33.34 | $164.65 |
| 52 Week High | $83.40 | $213.50 |
Technical Indicators
Market Signals| Indicator | DD | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 94.52 | 59.09 |
| Support Level | $41.49 | $198.84 |
| Resistance Level | N/A | $211.00 |
| Average True Range (ATR) | 1.82 | 4.66 |
| MACD | 5.85 | -0.22 |
| Stochastic Oscillator | 94.61 | 68.88 |
Price Performance
Historical ComparisonAbout DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.